Alpha Peptides® research library
The KLOW component report records a measured amount for each of the four ingredients in the submitted sample. Here are the results for source batch 2026-06 and how that batch connects to the KLOW research pens we supply in the UK.
The report behind the figures
Janoshik report #167220 identifies batch 2026-06, with analysis dated 18 June 2026. Its sample label reads CU50 + TB10 + BC10 + KPV10, 80mg, KLOW80.
The document is a supplier-provided source report. Alpha Peptides® publishes its own analytical summary of the KLOW material and can provide the source report on request. The summary and the laboratory report are separate documents.
What the KLOW sample contained
| Reported component | Result |
|---|---|
| GHK-Cu | 55.54mg |
| TB-500 (TB4) | 10.02mg |
| BPC-157 | 10.46mg |
| KPV | 11.18mg |
The GHK-Cu entry also separates the result into 49.27mg GHK and 6.27mg copper. Together they make the reported 55.54mg. Adding the copper again would double-count it.
KPV appears in the report’s comments field, where its measured amount is recorded as 11.18mg. TB-500 is labelled “TB-500 (TB4)” in the results table. These details are preserved here so the figures can be followed back to their source.
Why do the results total 87.20mg for an 80mg product?
Adding the four reported measurements gives 87.20mg. The sample’s 80mg label describes the nominal formulation: 50mg GHK-Cu and 10mg each of TB-500, BPC-157 and KPV.
A nominal formulation is the stated product specification. An analytical result is a measurement of the material submitted to the laboratory. The figures therefore serve different purposes. This report records a measured total above the nominal label; it does not explain the reason for the difference.
The result is specific to the submitted sample. It is not a promise that each vial or pen contains precisely that measured total.
How the vial batch connects to our KLOW pens
We prepare our current KLOW research pens from KLOW vial batch 2026-06. The report therefore relates to the source material used in their preparation.
The finished dispensing pen was not the sample analysed in this component report. Its preparation and presentation are separate from the component measurements recorded for the source sample.
Amounts, purity and research findings
The values above are amounts expressed in milligrams. They are not purity percentages. The GHK and copper breakdown is part of the GHK-Cu measurement, rather than an additional peptide component.
The report also answers a different question from a research paper. A component analysis measures the submitted material; a biological study investigates what happens under experimental conditions. These results do not demonstrate how KLOW behaves in cells, animals or people.
Our KLOW composition guide explains the four ingredients and summarises selected research on individual compounds.
KLOW documentation for UK customers
Alpha Peptides® is based in the UK and delivers exclusively to UK addresses, with dispatch from Kent. Our KLOW 80mg research pen page brings together the formulation, presentation and current availability.
The KLOW analytical summary is available in our documentation library. For the source report or a query about an order, email info@alpha-peptides.co.uk.
For laboratory and in vitro research only. Not for human consumption, veterinary use, or medical, therapeutic, cosmetic, diagnostic or administration purposes.
Source document
Janoshik test report #167220. Sample: CU50 + TB10 + BC10 + KPV10, 80mg, KLOW80. Batch: 2026-06. Analysis date: 18 June 2026. Figures transcribed from the supplied report copy.